Jasper Therapeutics Reveals Treatment of First Patient in the Phase 1/2 Study of JPS191 for Fanconi Anemia

Jasper Therapeutics, Inc. JSPR dosed first patient in the Phase 1/2 clinical study of its drug candidate JPS191 as a conditioning agent in the treatment of Fanconi Anemia.

The company has sponsored research agreement with Stanford Medicine to conduct the clinical study of JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.

Ronald Martell, President and CEO, said, “There is a compelling need in this patient population for a non-toxic conditioning regimen, and we are very pleased to support this effort to seek therapeutic advances for these patients, We look forward to continuing our collaboration and advancing the study of JSP191 to the next phase of development.”

Rajni Agarwal, MD, Professor of Pediatrics, Stanford University School of Medicine, commented : “The objective of the study is to develop a cell therapy for FA which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor, after using JSP191 as a part of conditioning.”

Fanconi Anemia (FA) is a rare but serious blood disorder that prevents the bone marrow from making sufficient new red blood cells.

Jasper Therapeutics shares are trading up 4 percent at $3.09

Posted In: BiotechNewsPenny StocksHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.